Reference | E 1) | Infant’s Immune prophylaxis 2)(schedule/month ) | Sample size (n) | Newborn | 7-12month infant | >12 month child | |||
---|---|---|---|---|---|---|---|---|---|
HBsAg-pos | HBsAb-pos | HBsAg-pos | HBsAb-pos | HBsAg-pos | HBsAb-pos | ||||
1 | T: HBIG50 IU(0) + PDV5ug | T:36 | NR | NR | T:4 | T:32 | NR | NR | |
(0.5,1.5,2.5); C: PDV5ug (0.5,1.5,2.5) | C:38 | C: 9 | C:30 | ||||||
Sha 1985 [62] | 1 | T: HBIG 0.5 ml(0) + PDV 20ug (0,1,2,12); | T:19 | T:13 | T:18 | T:4 | T :10 | NR | NR |
C: PDV 20 ug(0,1,2,12) | C:10 | C:7 | C:0 | C:1 | C:5 | ||||
Wu 1986 [63] | 1 | T : HBIG 1 ml(0) + PDV 20ug (1,2,3) | T:13; | T:1; | NR | NR | NR | NR | NR |
C : PDV 20 ug(1,2,3) | C:6 | C:0 | |||||||
Farmer 1987 [64] | 1 | T: HBIG 0.25 ml (25 IU/kg)(0,1.5), | T:21 | NR | NR | T:3 | T:17 | NR | NR |
PDV5 ug(0,1.5, 6) C: PDV5 ug (0,1.5,6) | C:18 | C:4 | C:13 | ||||||
Theppisai 1987 [65] | 1 | T: HBIG 200 IU(0) + PDV 10 ug (0,1,6) | T:27 | NR | NR | T:2 | NR | NR | NR |
C: PDV 10 ug(0,1,6) | C:18 | C:2 | |||||||
1 | T: PDV3 ug(0,1,2,6) + HBIG(0) | T:64 | NR | NR | T:8 | NR | T:9 | T:47 | |
C: PDV3 ug(0,1,2,6) | C:64 | C:15 | C:15 | C:52 | |||||
Assateerawatt 1993 [68] | 1 | T:HBIG100IU(0) + RV20 ug (0,1,2,12) | T:30 | NR | NR | T:1 | T:25 | T:1 | T:24 |
C: RV20 ug(0,1,2,12) | C:30 | C:2 | C:22 | C:3 | C:21 | ||||
Li 1994 [69] | 1 | T : HBIG 200 IU(0) + PDV (0,1,6) | T1:20; C1:22 | T1:7; C1: 7; | T1:18;C1:3 | T1:1; C1:3 | T1:16; C1:19 | NR | NR |
C : PDV (1,2,3). | T2:20; C2:21 | T2:7; C2: 8; | T2:9; C2:2 | T2:7; C2:7 | T2:17; C2:11 | ||||
PDV including 10 ug, 20 ug and 30 ug | T3:22; C3:21 | T3:7; C3: 7 | T3:9; C3:2 | T3:1; C3:2 | T3:20; C3:20 | ||||
Zhao 1994 [70] | 1 | T : HBIG 60 IU(0) + V 10 ug (0,1,6) | T:40 | T:2 | T:35 | T:2 | T:36 | NR | NR |
C : V 10 ug(0,1,6) | C:26 | C:5 | C:9 | C:7 | C:15 | ||||
Kang 1995 [71] | 1 | T: HBIG 200 IU(0,1) + RV1 10 ug (0,1,6) | T:44 | NR | NR | NR | NR | T: 0 | T: 43 |
C: RV1 20 ug(0,1,6) | C:41 | C: 5 | C: 35 | ||||||
1 | T: HBIG 100 IU(0) + RV 10 ug (0,1,6,60) | T:64 | T:1 | NR | T: 0 | T: 58 | T:1 | T:39 | |
C: RV 10 ug(0,1,6,60) | C:63 | C:3 | C:3 | C: 54 | C:3 | C:35 | |||
Lin 2000 [75] | 1 | T : HBIG 50 IU(0) + RV 10 ug (0,1,6) | T:31 | T:4 | T: 26 | NR | NR | NR | NR |
C : RV 10 ug(0,1,6) | C:39 | C:2 | C: 36 | ||||||
Meng 2001 [76] | 1 | T : HBIG 50 IU(0) + RV 10 ug (0,1,6) | T:50 | NR | NR | NR | NR | T:4 | T:45 |
C : RV 10 ug(0,1,6) | C:52 | C:7 | C:43 | ||||||
1 | T: HBIG 100 IU(0,1) + RV 20 ug (1,2,7) | T:104; C:241 | T:20; C :76 | NR | T:21; C:81 | NR | T:26; C:96 | NR | |
2 | C: PDV 20 ug(0,1,6) | T:157; C:122 | T:19; C:25 | NR | T:22; C:26 | NR | T:28;C:35 | NR | |
13) | T: HBIG0.5 ml(0) + PDV10 ug(0,1,2) | T:7; C:7 | NR | NR | T:1; C:1 | T:5;C:4 | NR | NR | |
2 | C: PDV10 ug(0,1,2) | T:17:C:14 | NR | NR | T:1; C:1 | T:13;C:13 | NR | NR | |
Xu 1995 [12] | 1 | T: HBIG 250 IU(0) + PDV 20 ug(0,1,6) | T:11; C:31 | NR | NR | T:1; C:10 | NR | T:1; C:10 | NR |
2 | C: PDV 20 ug(0,1,6) | T:17; C:29 | NR | NR | T:0; C:2 | NR | T:1; C:2 | NR |